UOC Oncoematologia AOU L.Vanvitelli
Welcome,         Profile    Billing    Logout  
 6 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ciardiello, Fortunato
COLSTAR, NCT05223673 / 2021-003151-41: Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer

Terminated
3
7
Europe, Japan, US
Futuximab/modotuximab, Trifluridine/Tipiracil
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Metastatic Colorectal Cancer
06/23
06/23
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy

Recruiting
2
173
Europe
Cetuximab, Erbitux, Avelumab, Bavencio
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Cancer
07/25
07/25
CAPRI 2 GOIM, NCT05312398: Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

Active, not recruiting
2
219
Europe
Cetuximab, Erbitux, FOLFIRI, FOLFOX regimen, FOLFOX, Irinotecan
University of Campania "Luigi Vanvitelli"
Metastatic Colorectal Adenocarcinoma
08/25
06/26
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
NCT06270602: The ONCOCAMP Study

Recruiting
N/A
15000
Europe
Data collection (retrospective), Data collection (prospective)
National Cancer Institute, Naples
Oncology
01/25
07/26
RATIONAL, NCT05918666: National Register of Actionable Mutations

Recruiting
N/A
3000
Europe
Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l.
Solid Tumours in Advanced Stages
10/26
10/26

Download Options